Drugs / SLA-SE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02071758 | Apr 2014 → Dec 2015 | visceral leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLA-SE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02071758 ↗ |
| Route | Intramuscular | “Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56.” NCT02071758 ↗ |